Background About half of twin pregnancies deliver preterm, and it is unclear whether any intervention reduces this risk.
Main results We included 23 trials (all but three were considered to have a low risk of bias) comprising 6626 women with twin pregnancies. None of the interventions significantly reduced the risk of preterm birth overall at <34 or <37 weeks of gestation, or neonatal death, our primary outcomes, compared to a control group. In women receiving vaginal progesterone, the relative risk (RR) of preterm birth <34 weeks of gestation was 0.82 (95% CI 0.64-1.05, seven studies, I
2 36%), with a significant reduction in some key secondary outcomes, including very low birthweight (<1500 g, RR 0.71, 95% CI 0.52-0.98, four studies, I 2 46%) and mechanical ventilation (RR 0.61, 95% CI 0.45-0.82, four studies, I 2 22%).
Introduction
Preterm birth, i.e. birth before 37 completed weeks of gestation, is the leading cause of mortality and a major cause of morbidity in children. 1, 2 Although twin pregnancies represent 1-3% of all pregnancies in Europe and the USA, they account for 17-20% of all preterm births, 3, 4 with about half of twin pregnancies delivering before 37 weeks of gestation. 3, 4 Unlike in singleton gestations, where meta-analyses of individual interventions, i.e. progesterone, pessary, or cerclage, each showed some benefit, [5] [6] [7] previously published meta-analyses of progesterone or cerclage have not found a reduction in rates of preterm birth for twins. 5, [8] [9] [10] [11] The search strategies for progesterone were executed in 2013 or earlier, but recent trials have been published. For cerclage, the search strategies were executed in 2014 or earlier. Additionally, to our knowledge, no meta-analysis of pessary in twins has been performed, despite the publication of randomised trials, and the fact that it is reasonable to hypothesise that such a mechanical intervention could provide benefit in twin gestations, given that the higher risk of preterm birth in twins may partly arise from the stretching of the uterus and pressure on the cervix. 12 Our objective was to complete an overarching synthesis of the current evidence in twin gestations of the effectiveness of the main methods of preventing preterm birth, progesterone, cerclage, or pessary, and compare these interventions using pairwise and network meta-analysis, data permitting.
Methods
We registered our protocol in the PROSPERO database (CRD42015016166).
Information sources and search strategy
We executed our search strategy in five electronic databases from their inceptions until 25 January 2016 (Medline, EMBASE, CINAHL, Cochrane CENTRAL, and ISI Web of Science), without any language restriction (for the complete search strategy, see Appendix S1). We screened reference lists of previous systematic reviews and all included studies. In addition, we contacted experts in the area to inquire for additional studies that we might have missed.
Eligibility criteria
We included studies in which women with a twin pregnancy were randomised to an intervention for the prevention of preterm birth (any type of progesterone, cervical cerclage, cervical pessary, or any combination of these) or to a control group (e.g. placebo or treatment as usual) or another of the mentioned interventions (as we had planned to do a network meta-analysis if enough data were to be identified). We excluded any other study designs including cluster-randomised trials, non-peer reviewed literature, studies published only as abstracts, or studies assessing the prevention of preterm birth in women with contractions, i.e. tocolytics. We contacted authors of studies where results of singleton, twins, and/or higher order pregnancies were not stratified to ask for the stratified data of the originally published outcomes.
Our primary outcomes were preterm birth at <34 and <37 weeks of gestation, separating them into spontaneous preterm birth or induced preterm birth, where possible. In addition, after publishing the protocol, but before analysing the data, we decided to add neonatal death to our primary outcomes.
Our infant secondary outcomes were: mortality (i.e. perinatal death, miscarriage, and stillbirth), preterm birth (<24, <28, <30, and <32 weeks of gestation), gestational age at birth, low birthweight (<2500 g), small for gestational age (below tenth, fifth, and third percentiles), birthweight, admission and length of stay in the neonatal intensive or special care unit (NICU), morbidity related to prematurity (i.e. respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular haemorrhage, periventricular leukomalacia, necrotising enterocolitis, sepsis), congenital anomalies, masculinisation of female fetuses, umbilical cord pH < 7.1, and low Apgar score at 5 minutes. We decided to record very low birthweights of <1500 g and any other measure of preterm birth shortly after we started collecting data.
Our maternal secondary outcomes were: mortality, preterm premature rupture of membranes (PPROM), intervention side effects (e.g. infection, vaginal discharge, bleeding, fever, repositioning or removal of pessary), length of inpatient antepartum stay, number of outpatient visits, and caesarean section.
Data extraction and assessment of risk of bias
Two independent reviewers (AJ and OL) screened titles, abstracts, and the full text of potentially relevant papers, with a third assessor (SM) available when disagreements could not be resolved by discussion. If necessary, we contacted the authors of the original studies to confirm the inclusion criteria and to provide clarifications on the published data.
Two independent reviewers (AJ and either OL or CP) extracted data on study characteristics, potential effect modifiers, and outcomes using a piloted data collection form. For binary outcomes we extracted raw data (e.g. 2 9 2 tables) or effect sizes (e.g. odds ratios, ORs) and confidence intervals. For continuous outcomes, we extracted raw data for each group (mean, standard deviation, and group size) or effect sizes (e.g. mean difference) and confidence intervals.
The same reviewers assessed risk of bias using the Cochrane Risk of Bias tool. 13 This tool assesses seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. Each domain was assessed as having a low, unclear, or high risk of bias. Although the Cochrane Risk of Bias tool does not provide an overall risk of bias assessment, we applied the following algorithm (as used in previous reviews): the overall risk of bias was considered low if four or more domains were rated as low risk (not counting 'other biases'), with at least one of them being sequence generation or allocation concealment. 14 
Data synthesis and statistical analyses
We had planned to carry out, data permitting, Bayesian random-effects network meta-analyses. After considering the results of the standard pairwise inverse variance random-effects meta-analyses of each intervention versus a control group, however, we considered that a network meta-analysis would be uninformative and decided to perform separate pairwise random-effects meta-analyses only (DerSimonian and Laird), 15 for each intervention compared with a control group, using REVIEW MANAGER 5.3. Relative risks (RRs) and mean differences (MDs) were calculated, with their corresponding 95% confidence intervals (95% CIs). We did not test for heterogeneity (i.e. v 2 or Q tests), but quantified this using the I 2 statistic. 16 Publication bias was assessed using funnel plots and Duval and Tweedie's trim-and-fill method (when the funnel plot showed asymmetry).
Unit of analysis
Given that several of our outcomes are assessed at the level of the infant, and not the pregnancy (such as respiratory distress syndrome), these outcomes should ideally be analysed by taking into account the non-independence, that is the clustering of the data, in twins. 17 Given that most of the primary studies did not do this, however, we were also unable to do so.
Subgroup and sensitivity analyses
We planned the following subgroup analyses for the primary outcomes (data permitting): route of administration of progesterone and type of cerclage. We additionally planned subgroup analyses by cervical length ≤25 mm, previous preterm birth, parity, cervical insufficiency, and infant sex. A sensitivity analysis examining studies with a low risk of bias was planned. Post hoc we decided not to limit subgroup analyses to primary outcomes alone.
Results
Our search strategy yielded 12 280 results, from which we deleted 4371 duplicates and excluded 7715 references based on their titles and abstracts. Screening references yielded 99 additional entries and an additional study was located after contacting experts in the field. After assessing the full text of the remaining 294 references, 23 studies met our inclusion criteria, with 6626 women ( Figure S1 ).
Study characteristics
Sixteen studies compared progesterone with placebo or no intervention/treatment as usual, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] four assessed cerclage, [34] [35] [36] [37] and three assessed pessary (Table 1) . [38] [39] [40] No study compared different interventions directly with each other or allocated women randomly to a combination of two interventions (e.g. progesterone and cerclage) or more. In total, we identified five studies that had not been included in a meta-analysis before: two assessing progesterone and three assessing pessary. 32, 33, [38] [39] [40] All studies of intramuscular progesterone used 17-alphahydroxyprogesterone caproate (17-OHPC). Four studies included women with a short cervix (variously defined). According to the World Bank classification, 41 20 studies were conducted in high-or upper middle-income countries, and two were conducted in lower middle-income countries. One multi-centre, multinational study recruited 28 women from a low-income country; however, it is unclear how many of these bore a twin pregnancy. Therefore, less than 0.4% of the women in the studies assessing progesterone and none of the women receiving other interventions were from low-income countries. All but three studies were considered to have a low risk of bias (Figure S2 ; details provided as Appendix S2). Across the domains of the risk of bias tool, the mean proportion of agreement between raters was 0.85 between AJ and OL, and 0.68 between AJ and CP (proportions are presented as there are known problems of the Kappa statistic leading to low Kappa values despite high agreement). 42 
Primary outcomes
In separate pairwise meta-analyses, compared with control, none of the interventions significantly reduced the risk of any of our primary outcomes: preterm birth at <34 or <37 weeks of gestation, and overall neonatal death ( Table 2) . Similar results were found for spontaneous preterm birth (Table 3) . Given these negative results we deemed that network meta-analyses would be uninformative, and therefore did not perform them. Following Sterne et al.'s recommendations, 43 publication bias was assessed in meta-analyses with more than ten studies. No publication bias was suspected ( Figure S3 ). 
Secondary outcomes
Similar to the primary outcomes, none of the interventions studied significantly reduced the risk of most of our secondary outcomes (Tables 3 and 4 Tables 3 and 4) .
Subgroup analyses
In the subgroup of women receiving vaginal progesterone, the relative risk of preterm birth <34 weeks of gestation was 0.82 (95% CI 0.64-1.05, seven studies, 1751 women, I 2 36%), with significant decreases in some key secondary outcomes that are sequelae of preterm birth, including very low birthweights of <1500 g (RR 0.71, 95% CI 0.52-0.98, four studies, 3079 women, I 2 46%), and mechanical ventilation (RR 0.61, 95% CI 0.45-0.82, four studies, 1792 women, I 2 22%). Although overall neonatal death was not found to be affected, one study reported a reduction in early neonatal death (RR 0.49, 95% CI 0.33-0.73, one study, 439 women). The risk of caesarean section was reduced slightly (RR 0.94, 95% CI 0.90-0.99, six studies, 2140 women, I 2 0%). In contrast, intramuscular progesterone (17-OHPC) significantly increased the risk of NICU admission (RR 1.35, 95% CI 1.13-1.60, two studies, 1619 women, I 2 0%), and was associated with slightly lower Apgar scores in one study (MD À0.60, 95% CI À1.14 to À0.06, one study, 60 women). There was a significant reduction in the risk of retinopathy of prematurity, however (RR 0.30, 95% CI 0.10-0.90, three studies, 1320 women, I 2 6%; Table S1 ).
In the subgroup of women with a cervical length of 25 mm or less, including one study of cervical length <15 mm, nine studies (five progesterone, two cerclage, and two pessary) reported data, but none of our primary outcomes were significantly affected (Table S2) . Among the secondary outcomes reported for this subpopulation, gestational age was increased by progesterone (per vagina in all studies, MD 1.00 weeks, 95% CI 0.36-1.64 weeks, two studies, 259 women, I 2 0%) and pessary (MD 2.20 weeks, 95% CI 1.03-3.37 weeks, one study, 134 women). Progesterone (per vagina in all studies) also reduced the risk of very low birthweights of <1500 g (RR 0.45, 95% CI 0.32-0.63, two studies, 500 women, I 2 0%), mechanical ventilation (RR 0.47, 95% CI 0.32-0.69, one study, 439 women), and early neonatal death (RR 0.49, 95% CI 0.33-0.73, one study, 439 women).
A single study in women with previous preterm birth or miscarriage found no significant effect of progesterone on preterm birth at <37 or <32 weeks of gestation, or on other secondary outcomes. 26 We were unable to perform subgroup analyses according to type of cerclage because McDonald cerclage was used in all cases except for a minority of Shirodkar procedures reported in MacNaughton et al. (1993 With the lack of stratified data, we could not perform the other subgroup analyses in the protocol regarding parity, cervical insufficiency, and infant sex.
Sensitivity analyses
Examining studies with a low risk of bias yielded very similar results for preterm birth at <34 and <37 weeks of gestation, and neonatal death. Similar results were also found for secondary outcomes (Table S3) .
Individual study data for primary and secondary outcomes, as well as subgroup and sensitivity analyses, are reported in Appendix S3.
Discussion

Main findings
In the first over-arching synthesis to our knowledge in twin pregnancies, none of the overall interventions, i.e. progesterone, cerclage, or pessary, prevented preterm birth, neonatal death, or most secondary outcomes; however, in the subgroup of women receiving vaginal progesterone there was a trend towards a reduction in preterm birth at <34 weeks of gestation, and there were significant decreases in some secondary outcomes that are sequelae of preterm birth, including very low birthweights of <1500 g. In contrast, intramuscular progesterone (17-OHPC) increased the risk of some adverse outcomes. In women with a short cervix of 25 mm or less, vaginal progesterone appeared to significantly decrease some secondary outcomes. Pessary improved gestational age at birth by 2 weeks in this population.
Strengths and limitations
This is a comprehensive synthesis of the literature on the prevention of preterm birth in women with a twin pregnancy, a group with approximately a 50% chance of preterm birth. 3, 4 It includes the first systematic review and meta-analysis of the efficacy of pessary in twins, and an updated synthesis of progesterone and cerclage, which extended previous findings. Although we did not perform Significant results are set in bold. Cells with no results are empty. *One study reported this outcome, but the effect size was not estimable (Norman 2009 22 : 0/247 versus 0/247 cases in the progesterone and placebo group, respectively). network meta-analyses because of the lack of benefit of the interventions in standard pairwise meta-analyses, this overarching synthesis of the three interventions will enable clinicians to understand their efficacy in relation to each other. A limitation of our systematic review is the lack of robust primary data on cerclage: only 44 women received cerclage in four studies, compared with thousands of women receiving progesterone (2362) and pessary (1050). In addition, only one of the four studies assessing cerclage focused only on twins, whereas the other three enrolled both singletons and twins without stratifying the randomisation process; hence, it is possible that some baseline characteristics were not evenly distributed in some outcomes, and a multivariate analysis with individual participant data (if available) would be more appropriate. Although preterm birth is a worldwide problem, few primary data are available from low-income countries, although we do not anticipate markedly different results there. As the primary studies generally did not report data adjusted for the correlated nature of twins, we could not take this into account in our meta-analyses. This is likely to have led to an underestimation of the standard errors, yielding confidence intervals that are artificially narrow for infant outcomes; however, given that confidence intervals were only marginally wider in a study assessing the effect of ignoring the correlation between twins, 17 we do not think that our results would markedly change. In addition, this would not apply to preterm birth or other outcomes assessed at the level of the pregnancy (Tables 2  and 3 ). Given the reported data we could study the subpopulation of women with a short cervix only, but not with previous preterm birth. Schuit's individual participant data meta-analyses on progesterone did not find markedly different results in this subgroup, however (neither did Romero et al. in their subgroup analyses, although they included only women with a short cervix in their study). 8, 9 Finally, many of our meta-analyses included a small number of studies, a scenario that remains challenging for random-effects meta-analysis (both using the DerSimonian-Laird and the Knapp-Hartung methods), and for which no clear guidance exists. 44 We therefore advise caution in interpreting these results.
Interpretation
To our knowledge, this is the first systematic review that presents the meta-analyses of the effect of progesterone, cerclage, and pessary in a way that allows for an easy comparison, which is much more challenging when results of different reviews, with their own particularities in terms of inclusion and exclusion criteria, and definitions of outcomes and subgroups, have to be compared. This is also the first systematic review to synthesise the effect of pessary in twin gestations, which has been assessed in a pooled sample of over 2000 women. As in previous reviews, Significant results are set in bold. Cells with no results are empty. *One additional study could not be pooled because the effect size was not estimable (Norman 2009 22 : 0/494 versus 0/494 cases in the progesterone and placebo group, respectively). **One additional study could not be pooled because the effect size was not estimable (Awwad 2014 31 : 0/382 versus 0/188 cases in the progesterone and placebo group, respectively). ***One additional study could not be pooled because the effect size was not estimable (Goya 2016 39 : 0/136 versus 0/130 cases in the pessary and no intervention group, respectively).
vaginal progesterone was associated with a significant reduction in several infant secondary outcomes; however, unlike results previously reported by Schuit et al. and Romero et al., 8, 9 this was not limited to women with a short cervix. Additionally, we identified a trend towards a reduction in preterm birth <34 weeks of gestation in women receiving vaginal progesterone, not found in previous reviews. This could be explained by two recent studies, 32 ,33 that were not included in the previous systematic reviews of progesterone in twin pregnancies, 5, 8, 9 in which the literature searches ended in 2011 (Romero et al. 9 ) and in 2013 (Dodd et al. 5 and Schuit et al. 8 ). We additionally compared our findings with the two previous systematic reviews of cerclage in twin pregnancies conducted by Rafael et al. 10 and Saccone et al. 11 Their literature searches ended in 2014, although there have not been additional trials published since then, which means that no study on the effect of cerclage in twin pregnancies has been published since 2004. We did not find any positive or negative effects of cerclage, but with the inclusion of unpublished (non peer-reviewed) data in their analysis the previous reviews reported that neonates of women with a short cervix were at an increased risk of very low birthweight and respiratory distress syndrome, 10, 11 as well as at an increased risk of a composite outcome of perinatal death and neonatal morbidity. 10 
Conclusion
In twin gestations, although no overarching intervention was beneficial for the prevention of preterm birth and its sequelae, vaginal progesterone improved some important secondary outcomes in women overall and in women with short cervices. There were very limited data on cerclage. Further research is required to reduce the risks of preterm birth and its sequelae in twin pregnancies, including the use of combinations of therapies.
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